Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of AC-201 Tablets in Subjects With Moderate-to-severe Plaque Psoriasis

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of AC-201 Tablets in Subjects With Moderate-to-severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AC-201-Accropeutics (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

  • 04 Sep 2025 According to Accropeutics media release,the company announced that it will present results from the study at the European Academy of Dermatology & Venereology (EADV) Congress, being held September 17-20th, in Paris.
  • 29 Aug 2025 Status changed from recruiting to completed, according to Accropeutics media release.
  • 20 May 2025 Primary endpoint (Percentage of subjects achieved Psoriasis Area Severity Index (PASI) 75 at Week 12) has been met, according to an Accropeutics Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top